Google's AI drug discovery firm, Isomorphic Labs, is reportedly raising over $2 billion in new funding led by Thrive Capital.
Why it matters
This substantial funding round for Isomorphic Labs signifies a major investment in the application of AI to drug discovery. It underscores the growing confidence in AI's potential to accelerate and revolutionize the pharmaceutical industry, potentially leading to faster development of new treatments and therapies. The investment also reflects a broader trend of large tech companies leveraging their AI expertise for commercial ventures in critical sectors like healthcare.
Google's AI company that helps find new medicines is getting a lot of money, over $2 billion. This money will help them build better AI tools to discover drugs faster and expand their work around the world.
Alphabet is issuing yen bonds for the first time to fund its AI initiatives, mirroring a trend among Big Tech companies using debt markets for AI investments.
Read on Economic Times Tech →Google is reportedly considering manufacturing AI servers in India, following HP's lead, as part of its global supply chain diversification strategy and in conjunction with its substantial AI hub investment in Visakhapatnam.
Read on Economic Times Tech →OpenAI employees cashed out significant equity in a secondary sale, valuing the AI company at $400 billion.
Read on Economic Times Tech →